Document is current
Any future updates will be listed below
-
Authors
Kalidindi, Teja Muralidhar
Lee, Sang-Gyu
Jou, Katerina
Chakraborty, Goutam
Skafida, Myrto
Tagawa, Scott T.
Bander, Neil H.
Schoder, Heiko
Bodei, Lisa
Pandit-Taskar, Neeta
Lewis, Jason S.
Larson, Steven M.
Osborne, Joseph R.
Pillarsetty, Naga Vara Kishore https://orcid.org/0000-0002-1750-7436
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA207645, R35 CA232130, P30 CA008748)
DOD Prostate Cancer Research Program (W81XWH-19-1-0536)
- License Information
-
More Information
Article History
Received: 31 July 2020
Accepted: 6 December 2020
First Online: 25 January 2021
Compliance with ethical standards
:
: Dr. Tagawa has served as a consultant for Endocyte and Advanced Accelerator Applications/Novartis and has received institutional research funding from Advanced Accelerator Applications/Novartis. Cornell University holds the intellectual rights for anti-PSMA antibody technology invented by Dr. Bander, that has have been licensed to BZL Biologics, LLC. NB holds equity in BZL biologics and Telix Pharmaceuticals (also serves as uncompensated SAB). All other authors declare no conflict of interest.
: All animal studies were approved by MSKCC-IACUC that ensures that all international, national, and institutional guidelines for the care and use of animals were followed. This study does not contain any studies with human participants.
